Literature DB >> 16480948

WISP-3 functions as a ligand and promotes superoxide dismutase activity.

Leila Davis1, Yi Chen, Malini Sen.   

Abstract

WISP-3 (Wnt1 inducible secreted protein-3) mutations have been linked to the connective tissue diseases progressive pseudorheumatoid dysplasia and polyarticular juvenile idiopathic arthritis, both of which are accompanied by disorders in cartilage maintenance/homeostasis. The molecular mechanism of WISP-3 mediated effects in the sustenance of cartilage has not been described in detail. Our previous study illustrates the potential role of WISP-3 in regulating the expression of cartilage-specific molecules that sustain chondrocyte growth and cartilage integrity. The present study was conducted to investigate the mode of action of WISP-3 in greater detail. Experimental results depicted here suggest that WISP-3 can function as a ligand and signal via autocrine and/or paracrine modes upon being secreted by chondrocytes. Furthermore, apart from regulating collagen II and aggrecan expression, WISP-3 may also promote superoxide dismutase expression and activity in chondrocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480948     DOI: 10.1016/j.bbrc.2006.01.132

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Proepithelin stimulates growth plate chondrogenesis via nuclear factor-kappaB-p65-dependent mechanisms.

Authors:  Shufang Wu; Weijin Zang; Xu Li; Hongzhi Sun
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

Review 2.  Progressive pseudorheumatoid dysplasia: a rare childhood disease.

Authors:  Sofia Torreggiani; Marta Torcoletti; Belinda Campos-Xavier; Francesco Baldo; Carlo Agostoni; Andrea Superti-Furga; Giovanni Filocamo
Journal:  Rheumatol Int       Date:  2018-10-16       Impact factor: 2.631

Review 3.  Disorders of the growth plate.

Authors:  Chanika Phornphutkul; Philip A Gruppuso
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-12       Impact factor: 3.243

4.  The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.

Authors:  Yukio Nakamura; Gilbert Weidinger; Jennifer O Liang; Allisan Aquilina-Beck; Keiko Tamai; Randall T Moon; Matthew L Warman
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 5.  Input of microenvironmental regulation on colorectal cancer: role of the CCN family.

Authors:  Cheng-Chi Chang; Been-Ren Lin; Tai-Sheng Wu; Yung-Ming Jeng; Min-Liang Kuo
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 6.  Targeting CCN Proteins in Rheumatoid Arthritis and Osteoarthritis.

Authors:  Iona J MacDonald; Chien-Chung Huang; Shan-Chi Liu; Yen-You Lin; Chih-Hsin Tang
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

7.  WISP3 mutational analysis in Indian patients diagnosed with progressive pseudorheumatoid dysplasia and report of a novel mutation at p.Y198.

Authors:  V Madhuri; M Santhanam; K Rajagopal; L K Sugumar; V Balaji
Journal:  Bone Joint Res       Date:  2016-07       Impact factor: 5.853

8.  Novel WISP3 mutations causing progressive pseudorheumatoid dysplasia in two Chinese families.

Authors:  Wenjin Yan; Jin Dai; Zhihong Xu; Dongquan Shi; Dongyang Chen; Xingquan Xu; Kai Song; Yao Yao; Lan Li; Shiro Ikegawa; Huajian Teng; Qing Jiang
Journal:  Hum Genome Var       Date:  2016-12-08

9.  CCN6 mutation detection in Chinese patients with progressive pseudo-rheumatoid dysplasia and identification of four novel mutations.

Authors:  Yingjie Wang; Ke Xiao; Yuemei Yang; Zhihong Wu; Jin Jin; Guixing Qiu; Xisheng Weng; Xiuli Zhao
Journal:  Mol Genet Genomic Med       Date:  2020-04-29       Impact factor: 2.183

10.  CYR61/CCN1 and WISP3/CCN6 are chemoattractive ligands for human multipotent mesenchymal stroma cells.

Authors:  Norbert Schütze; Rita Schenk; Jörg Fiedler; Thomas Mattes; Franz Jakob; Rolf E Brenner
Journal:  BMC Cell Biol       Date:  2007-10-31       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.